Porosome Therapeutics Announces Breakthrough Discoveries in Alzheimer’s Research
Porosome Therapeutics, Inc. had announced major progress in the fight against Alzheimer’s Disease (AD) with a first-of-its-kind therapeutic platform that addresses the root causes of the condition, rather than just managing symptoms.
In recent studies using FDA-recommended human brain organoid models, the company’s lead therapy showed rapid reversal of Alzheimer’s pathology within two weeks.
Results included a significant reduction in Tau protein, an FDA-recognised biomarker for AD. These findings support the potential for accelerated regulatory pathways.
Porosome Therapeutics’ approach restores porosomes – tiny cellular nanomachines responsible for neurotransmitter release – to repair damaged neuronal function. This “Reprogram, Restore, and Rescue” strategy aims to restore both cellular metabolism and communication, offering a disease-modifying treatment option.
At Porosome Therapeutics, our platform directly addresses the biological dysfunctions of Alzheimer’s. With biomarker-driven results and disease reversal in organoids, we are optimistic about the impact this therapy could have for millions of patients worldwide.
In addition, the company is using artificial intelligence (AI) to design decoy peptides that neutralise toxic beta amyloid proteins, protecting brain cells and preserving neurotransmission.
Together with small molecules to restore mitochondrial function and biologics that repair the porosome complex, these innovations define an entirely new therapeutic landscape for Alzheimer’s.
Porosome Therapeutics is expanding its pipeline to advance these discoveries, aiming to transform the future of Alzheimer’s treatment and care.
